Web Analytics Made Easy - Statcounter

top of page

Multiple Myeloma Clinical Trials - @ MD Anderson Cancer Center

MD ANDERSON multiple myeloma trials

NCT04270409

NCT04270409

NCT04879043

NCT04879043

ORIC-533

ORIC-533

NCT04270409

NCT04270409

1/32

Multiple Myeloma Clinical Trials - Currently Recruiting

Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

2022 - (R) NCT05347485

Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM

2022 - (R) NCT05336383

Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM

Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL

2021 - (R) NCT05121103

Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL

NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program Post CART

2021 - (R) NCT05064787

Evaluating the Feasibility of a Digital Health Coaching Program Post CART

NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM

2021 - (R) NCT05000450

Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM

NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM

2021 - (R) NCT04879043

Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM

NCT04855136: Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)

2021 - (R) NCT04855136

Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)

NCT04614636: FT538 in Subjects With Advanced Hematologic Malignancies

2020 - (R) NCT04614636

FT538 in Subjects With Advanced Hematologic Malignancies

NCT04582539: Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma

2020 - (R) NCT04582539

Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma

NDMM

NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)

2020 - (R) NCT04268498

Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)

NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC

2019 - (R) NCT04071457

Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC

NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

2019 - (R) NCT03989414

Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)

2019 - (R) NCT03901963

Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)

MGUS/SMM

NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

2021 - (R) NCT05136807

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis

2020 - (R) NCT04512235

Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis

NCT04504825: Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

2020 - (R) NCT04504825

Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)

2020 - (R) NCT04270409

Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)

NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM

2019 - (R) NCT03937635

Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM

NCT03631043: Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM

2018 - (R) NCT03631043

Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM

United States - Myeloma Clinical Trials | MCT Index (themyelomaclinicaltrials.com)

bottom of page